MAFLD is Associated with the Risk of Liver Fibrosis and Inflammatory Activity in HBeAg-Negative CHB Patients

References

• Yang JD, Gyedu A, Afihene MY, et al. Hepatocellular carcinoma occurs at an earlier age in africans, particularly in association with chronic Hepatitis B. Am J Gastroenterol. 2015;110(11):1629–1631. doi:10.1038/ajg.2015.289
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global hepatitis report, 2017; 2017. Available from: https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/. Accessed April 2017.
   Google Scholar
• Chinese national administration of disease prevention and control. Overview of the Chinese notifiable infectious diseases; 2018–2020. Available from: http://www.nhc.gov.cn/jkj/pgzdt/new_list.shtml. Accessed January 24, 2022.
   Google Scholar
• Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295(1):65–73.
   PubMed Web of Science ®Google Scholar
• Yang H-I, Lu S-N, Liaw Y-F, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347(3):168–174. doi:10.1056/NEJMoa013215
   PubMed Web of Science ®Google Scholar
• Tseng TC, Liu CJ, Hsu CY, et al. High level of Hepatitis B core-related antigen associated with increased risk of hepatocellular carcinoma in patients with chronic HBV infection of intermediate viral load. Gastroenterology. 2019;157(6):1518–1529 e1513. doi:10.1053/j.gastro.2019.08.028
   Web of Science ®Google Scholar
• Will H. HBcAg and HBeAg expression: how where, why or why not?. J Hepatol. 1991;13(Suppl 4):S66–S67.
   Web of Science ®Google Scholar
• Kramvis A, Kostaki EG, Hatzakis A, Paraskevis D. Immunomodulatory function of HBeAg related to short-sighted evolution, transmissibility, and clinical manifestation of Hepatitis B virus. Front Microbiol. 2018;9:2521. doi:10.3389/fmicb.2018.02521
   PubMed Web of Science ®Google Scholar
• Milich D, Liang TJ. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology. 2003;38(5):1075–1086. doi:10.1053/jhep.2003.50453
   PubMed Web of Science ®Google Scholar
• Wang J, Wu W, Yan X, et al. HBeAg negativity is associated with more advanced liver fibrosis in patients with chronic Hepatitis B: a propensity score-matching analysis. J Clin Gastroenterol. 2020;54(9):826–831. doi:10.1097/MCG.0000000000001291
   Web of Science ®Google Scholar
• Bai H, Liu H, Chen X, Xu C, Dou X. Influence of age and HBeAg status on the correlation between HBV DNA and hepatic inflammation and fibrosis in chronic hepatitis B patients. Dig Dis Sci. 2013;58(5):1355–1362. doi:10.1007/s10620-012-2479-7
   Web of Science ®Google Scholar
• Hui CK, Leung N, Yuen ST, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology. 2007;46(2):395–401. doi:10.1002/hep.21724
   PubMed Web of Science ®Google Scholar
• Eslam M, Sarin SK, Wong VW, et al. The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14(6):889–919. doi:10.1007/s12072-020-10094-2
   PubMed Web of Science ®Google Scholar
• Lin S, Huang J, Wang M, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int. 2020;40(9):2082–2089. doi:10.1111/liv.14548
   PubMed Web of Science ®Google Scholar
• Lee H, Lee Y-H, Kim SU, Kim HC. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a Nationwide Cohort Study. Clin gastroenterol hepatol. 2021;19(10):2138–2147.e10. doi:10.1016/j.cgh.2020.12.022
   PubMed Web of Science ®Google Scholar
• Tsutsumi T, Eslam M, Kawaguchi T, et al. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach. Hepatol Res. 2021;51(11):1115–1128. doi:10.1111/hepr.13685
   PubMed Web of Science ®Google Scholar
• Guerreiro GTS, Longo L, Fonseca MA, de Souza VEG, Álvares-da-silva MR. Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD? Hepatol Int. 2021;15(2):380–391. doi:10.1007/s12072-021-10157-y
   Web of Science ®Google Scholar
• Vitale A, Svegliati-Baroni G, Ortolani A, et al. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002–2033: the ITA.LI.CA database. Gut;2021. gutjnl-2021-324915. doi:10.1136/gutjnl-2021-324915
   Web of Science ®Google Scholar
• Myers S, Neyroud-Caspar I, Spahr L, et al. NAFLD and MAFLD as emerging causes of HCC: a populational study. JHEP Rep. 2021;3(2):100231. doi:10.1016/j.jhepr.2021.100231
   PubMedGoogle Scholar
• Wang X, Wu S, Yuan X, et al. Metabolic dysfunction-associated fatty liver disease and mortality among chinese adults: a Prospective Cohort Study. J Clin Endocrinol Metab. 2022;107(2):e745–e755. doi:10.1210/clinem/dgab644
   PubMed Web of Science ®Google Scholar
• Huang Q, Zou X, Wen X, Zhou X, Ji L. NAFLD or MAFLD: which has closer association with all-cause and cause-specific mortality?-Results from NHANES III. Front Med. 2021;8:693507. doi:10.3389/fmed.2021.693507
   Web of Science ®Google Scholar
• Huang J, Xue W, Wang M, et al. MAFLD criteria may overlook a subtype of patient with steatohepatitis and significant fibrosis. Diabetes Metab Syndr Obes. 2021;14:3417–3425. doi:10.2147/DMSO.S316096
   Web of Science ®Google Scholar
• Lee YB, Ha Y, Chon YE, et al. Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B. Clin Mol Hepatol. 2019;25(1):52–64. doi:10.3350/cmh.2018.0040
   PubMed Web of Science ®Google Scholar
• Charatcharoenwitthaya P, Pongpaibul A, Kaosombatwattana U, et al. The prevalence of steatohepatitis in chronic hepatitis B patients and its impact on disease severity and treatment response. Liver Int. 2017;37(4):542–551. doi:10.1111/liv.13271
   PubMed Web of Science ®Google Scholar
• Fan JG, Chen GF, Ji D, et al. Long-term disease progression and prevalence of metabolic syndrome in chronic hepatitis B patients with comorbid nonalcoholic fatty liver disease. Hepatology. 2016;64:538A–538A.
   Web of Science ®Google Scholar
• Hu D, Wang H, Wang H, et al. Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model. Hepatol Int. 2018;12(5):438–446. doi:10.1007/s12072-018-9877-7
   PubMed Web of Science ®Google Scholar
• Hui RWH, Seto WK, Cheung KS, et al. Inverse relationship between hepatic steatosis and hepatitis B viremia: results of a large case-control study. J Viral Hepat. 2018;25(1):97–104. doi:10.1111/jvh.12766
   PubMed Web of Science ®Google Scholar
• Li J, Yang HI, Yeh ML, et al. Association between fatty liver and cirrhosis, hepatocellular carcinoma, and HBsAg seroclearance in chronic hepatitis B. J Infect Dis. 2020;4:54.
   Google Scholar
• Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–1321. doi:10.1002/hep.20701
   PubMed Web of Science ®Google Scholar
• Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 1991;13(3):372–374. doi:10.1016/0168-8278(91)90084-O
   PubMed Web of Science ®Google Scholar
• Van kleef LA, Choi HSJ, Brouwer WP, et al. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. JHEP Rep. 2021;3(5):100350. doi:10.1016/j.jhepr.2021.100350
   PubMedGoogle Scholar
• Lin YP, Lin SH, Wang CC, et al. Impact of MAFLD on HBV-related stage 0/A hepatocellular carcinoma after curative resection. J Pers Med. 2021;11(8):684. doi:10.3390/jpm11080684
   Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005–2023. doi:10.1002/hep.25762
   PubMed Web of Science ®Google Scholar
• Choi HSJ, Brouwer WP, Zanjir WMR, et al. Nonalcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic Hepatitis B. Hepatology. 2020;71(2):539–548. doi:10.1002/hep.30857
   PubMed Web of Science ®Google Scholar
• Mak L-Y, Seto W-K, Hui RW-H, et al. Fibrosis evolution in chronic hepatitis B e antigen-negative patients across a 10-year interval. J Viral Hepat. 2019;26(7):818–827. doi:10.1111/jvh.13095
   PubMed Web of Science ®Google Scholar
• Enomoto H, Aizawa N, Nishikawa H, et al. Relationship between hepatic steatosis and the elevation of aminotransferases in HBV-infected patients With HBe-Antigen negativity and a low viral load. Medicine. 2016;95(17):e3565. doi:10.1097/MD.0000000000003565
   Web of Science ®Google Scholar
• Chen Y-C, Jeng W-J, Hsu C-W, Lin C-Y. Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study. BMC Gastroenterol. 2020;20(1):146. doi:10.1186/s12876-020-01289-w
   Web of Science ®Google Scholar
• Fattovich G, Olivari N, Pasino M, D’Onofrio M, Martone E, Donato F. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut. 2008;57(1):84–90. doi:10.1136/gut.2007.128496
   Web of Science ®Google Scholar
• Croagh CM, Bell SJ, Slavin J, et al. Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B. Liver Int. 2010;30(8):1115–1122. doi:10.1111/j.1478-3231.2010.02267.x
   PubMed Web of Science ®Google Scholar
• Burns GS, Thompson AJ. Viral hepatitis B: clinical and epidemiological characteristics. Cold Spring Harb Perspect Med. 2014;4(12):a024935. doi:10.1101/cshperspect.a024935
   Web of Science ®Google Scholar